|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 21, 2002; DOI 10.1182/blood-2002-07-2216.
REVIEW ARTICLE
From the Istituto di Anatomia e Istologia Patologica
and Divisione di Ematologia con TMO, University of Palermo, Palermo,
Italy.
Splenic marginal zone lymphoma (SMZL) is a specific low-grade
small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern
of involvement of various organs, especially bone marrow, and relative
indolent course. Tumor progression with increase of blastic forms and
aggressive behavior are observed in a minority of patients. Molecular
and cytogenetic studies have shown heterogeneous results probably
because of the lack of standardized diagnostic criteria. To date, no
definitive therapy has been established. Therapeutic options include
treatment abstention, splenectomy, splenic irradiation, and chemotherapy.
(Blood. 2003;101:2464-2472) Splenic marginal zone lymphoma (SMZL) is a
distinctive and well-characterized B-cell neoplasm that involves the
spleen and various organs. Although SMZL is accepted as an entity in
the World Health Organization (WHO) classification,1 its
histogenesis remains obscure.2
SMZL was originally recognized either after histopathologic
examination of surgically removed spleens as SMZL itself3
or by means of morphologic and immunophenotypical characterization of
circulating neoplastic lymphocytes as splenic lymphoma with villous
lymphocytes (SLVLs).4 Now it is quite clear that the 2 entities have the same pathologic basis but different expressions of
circulating cells.5,6 After the recognition of a peculiar intrasinusoidal bone marrow infiltration in SMZL with or without villous lymphocytes,7 the diagnosis can even be made with
the bone marrow biopsy alone.8,9 This feature is of great
help because it allows a definitive diagnosis to be made, avoiding an
unnecessary splenectomy. O'Reilly,10 who studied
retrospectively a large series of patients with splenomegaly, concluded
that in the case of splenomegaly of unknown origin, the invasive
procedure of choice for patients with hematologic associations could be a bone marrow biopsy.
For many years, the approaches to SMZL and SLVLs have been different.
SMZL has been prevalently diagnosed by pathologists and SLVL by
clinicians. Here we integrate the clinical and pathologic aspects of
SMZL, along with cytogenetics, molecular biology, special features, and
therapeutic options.
Incidence
Clinical presentation and laboratory findings
B symptoms such as fever and night sweats are rare. Similarly,
alterations in levels of serum albumin, lactic dehydrogenase (LDH), and
Occasionally diagnosis can be made on splenectomy specimens for traumatic or spontaneous rupture.17 Associated clinical conditions Autoimmune phenomena, such as primary biliary cirrhosis,18 rheumatoid arthritis,19 immune thrombocytopenia, appearance of lupus anticoagulant,20 and autoimmune hemolytic anemia,21-23 represent the most frequent associated conditions, even though in some cases they could be induced by treatment.24 A combination of warm autoimmune hemolytic anemia and pure red cell aplasia has been reported in a single patient.25A type II (IgM-IgG) cryoglobulin, detected in the serum, caused leukocytoclastic vasculitis in one patient.26 Clinical evolution SMZL is universally considered a low-grade lymphoma with an indolent clinical course. Many cases show a protracted uncomplicated evolution, a good response to splenectomy or chemotherapy, or even an unmodified clinical picture in the absence of any kind of treatment. The 5-year overall survival rate ranges from 65% to 78%16,27 (Figure 1). Even in the absence of treatment or complete response, the time to progression exceeds 5 years.27 After therapy, complete remission and good clinical hematologic response with no evidence of active disease were cumulatively observed in 80% of cases in the series of Chacòn et al,27 whereas partial response is observed in 13.3% of cases. Failure to obtain complete remission, involvement of nonhematopoietic sites at diagnosis, high performance status scores, and p53 expression are the 4 factors associated with poorer survival.27 Thieblemont et al28 reported a median survival of 10.5 years, which becomes significantly shorter in the presence of M component, elevated 2-microglobulin level, leukocyte count more than
20 000/µL, and lymphocytes more than 9000/µL. Despite its low
aggressive course, histologic progression with increased number of
blasts has been described in sporadic reports.29-31 In the
series of Camacho et al,31 blastic transformation occurred
in 13% of cases, which was lower than in follicular lymphoma (25%-60%) and mantle cell lymphoma (11%-39%) and similar to that observed in small lymphocytic lymphoma (1%-10%). Blastic
transformation correlated with higher mean proliferative index and
could be associated with p53 deletion but seems independent of p16INK4a
inactivation.32
Response to treatment and survival after transformation are poor. In contrast with the favorable survival for the group as a whole, patients who died from lymphoma had a median survival time of less than 2 years.16,27
Spleen Recognition of this kind of lymphoma started with the pathologic studies on surgically removed spleens. Several reports have outlined the pathologic picture.3,17,33-35 The spleen is enlarged, weighing from 270 to 5500 g with a median of 1750 g. The cut surface generally shows multiple, small-to-moderate gray-tan nodules throughout the parenchyma (Figure 2A). A diffuse variant with no nodule formation has been recently described.36
Histologically, the splenic architecture can be retained in initial phases. Hyperplastic white pulp shows expansion of marginal zones (Figure 2B), with frequent merging and coalescence. Residual reactive follicles with germinal centers can be occasionally noted. Germinal centers can be frequently involuted. Neoplastic cells extend from the marginal zone to the red pulp with variable involvement. In advanced phases, diffuse obliteration of splenic architecture is made by sheets of neoplastic cells that obscure white and red compartments; in these cases no residual follicular structures can be identified. Involvement of splenic sinuses is typical (Figure 2C-D). The sinuses are filled up with neoplastic cells morphologically identical to the cells seen in the marginal zones. Cytologically, the neoplastic cells are medium sized with roundish or slightly irregular nucleus, clumped chromatin, frequent small nucleolus, and a moderate amount of cytoplasm with distinct borders sometimes of villous appearance (Figure 2E). Bone marrow Bone marrow is invariably involved. Isolated and initial reports of cases with no bone marrow involvement can be attributed to subtle lymphoid infiltration, not easily recognized without immunohistochemical studies.7 Different types of infiltration have been described, namely, intrasinusoidal, interstitial, nodular, and even paratrabecular.6-8,13,17,24,33 However, intrasinusoidal infiltration can be considered highly characteristic of SMZL (Figure 2F-G); so far there is no report of intrasinusoidal infiltration in other kinds of low-grade B-cell lymphoma, with the exception of subtle infiltration in a proportion of cases of extranodal marginal lymphoma.37 Sometimes, perisinusoidal infiltration can be seen (Figure 2H). Different patterns of infiltration could be an expression of different phases of the disease; in early phases, the intrasinusoidal pattern prevails, whereas in advanced ones it tends to diminish and nodular formations tend to increase.38Peripheral blood Peripheral blood involvement is reported at different percentages. The previous provisional nomenclature of SMZL with or without villous lymphocytes exemplifies at best this variability. The amount of circulating cells can be so small that it cannot be detected. In obvious peripheral blood involvement, numerous mature B lymphocytes with pale cytoplasm, irregular cytoplasmic borders, and villous projections can easily be recognized (Figure 2I). Larger cells with prominent nucleoli can be seen in the aggressive variant.29Lymph nodes Involvement of hilar splenic lymph nodes is commonly observed in SMZL39 (Figure 2J). Peripheral lymph nodes can be involved as well, but to a lesser extent. Complete or partial effacement of lymph node architecture is made by a nodular lymphoid infiltrate. Neoplastic nodules can contain a central reactive follicular center. Sinuses are generally spared or can show variable degrees of dilation. The characteristic sinusoidal involvement seen in other organs has not been described in lymph nodes. Different expression of adhesion molecules in the various lymphoid compartments might explain, at least in part, this phenomenon. Extensive lymph node involvement can rarely produce diffuse replacement. Scattered blasts with nucleoli can sometimes be present, especially at the periphery of the nodules. A primary nodal counterpart of SMZL, occurring in the absence of splenomegaly, has been hypothesized and shows a similar histologic picture to that observed in hilar splenic lymph nodes of SMZL.40Liver Few data are available on liver involvement in SMZL.3,17,21,35,41 The liver is involved in almost 90% of cases prevalently showing nodular infiltration of portal tracts. Lobular invasion is reported to a lesser extent.21 However, no special reference is made on immunohistochemical studies. Liver biopsies in our patients show an invariable sinusoidal infiltration together with lymphoid nodules in portal tracts (V.F., personal data, 2002; Figure 2K-L).Other organs Rarely are nonhematolymphoid organs massively involved, at least at presentation. Involvement of nonhematopoietic sites is reported in 6.6% of cases in a recent series.27 Cutaneous involvement has been reported in 2 patients showing dermal tumoral infiltration located around cutaneous appendages and blood vessels with some degree of epidermotropism.42 Pleura localization is seen in 5% of cases in a large series.13 In a single patient of ours we found a massive perirectal localization of soft tissue. Sporadic soft-tissue involvement in SLVLs has been previously described by Orero et al43 in the thoracic region and by Yamazaki et al44 in perirenal area. Meningeal involvement has also been reported and can induce altered mental status and seizures.44,45
The B-cell nature of tumor cells in SMZL is well known. Table
1 shows the immunophenotypic profile of
SMZL. Positivity for CD20, CD45RA, CD45RB, CD79a, PAX5/BSAP, IgM, and
bcl2 and negativity for CD43, CD23, CD10, bcl6, and cyclin D1 are
constantly observed. Occasional positivity for CD5 has been reported in
a minority of patients,16,60 but it should be critically
analyzed. T-cell antigens are always negative. DBA44 gives variable
staining; weak positivity for acid phosphatase isoenzyme 5 (tartrate-resistant) is reported in a proportion of
cases.54 SMZL shares with nodal and extranodal marginal
lymphomas the absence of telomerase activity, which is conversely
highly expressed in other kinds of low-grade B-cell
neoplasms.61 High, low, or no expression of p27 has also been reported.55,56,62
Ultrastructural studies have been rarely performed. Hammer et al17 studied 11 of 14 cases of their series by electron microscopy. Neoplastic marginal zone cells have a moderately developed curvilinear rough endoplasmic reticulum, approaching that seen in plasmacytoid cells. The cytoplasmic ribosomes are either clustered or scattered. Nuclei generally show more evident and peripherally located nucleoli than in normal marginal zone cells. Cell-to-cell contact is characterized by surface interdigitations, focally prominent.
Among low-grade lymphoid neoplasias, various disorders can enter into differential diagnosis of SMZL. In most cases, a definitive diagnostic judgment can be reached after histologic examination along with immunohistochemical study in conjunction with clinical data. Only rarely are molecular biology and cytogenetics or ultrastructure helpful in distinguishing the various entities. Hairy cell leukemia Although circulating cells and clinical setting are similar in hairy cell leukemia (HCL) and SMZL, many distinguishing features make the differential diagnosis quite simple. In the bone marrow, hairy cells produce patchy infiltration with progressive replacement of normal hematopoietic series and low cellular density. Neoplastic infiltration is characteristically intermingled with extravasated red cells. The reticulin fiber content is almost invariably increased and accounts for the high frequency of "dry taps." In the spleen, HCL diffusely involves the red pulp, whereas the white pulp is atrophied. Cytochemically, hairy cells are diffusely and strongly positive for tartrate-resistant acid phosphatase (TRAP). The immunophenotype profile of HCL is similar to that of SMZL. However, HCL differs for CD25 and CD103 positivity. Ultrastructural analysis shows characteristic ribosome-lamella complex in hairy cell cytoplasm.B-CLL Morphologically, B-cell chronic lymphocytic leukemia (B-CLL) is composed of small mature lymphoid cells, with high nuclear-to-cytoplasm ratio, scant cytoplasm, and round nuclei with highly condensed chromatin and inconspicuous nucleolus. Admixed with these cells may be prolymphocytes and paraimmunoblasts, characterized by larger size and prominent nucleoli. In the bone marrow the pattern of infiltration can be interstitial, nodular, or diffuse, but never intrasinusoidal. Immunohistochemically, B-CLL differs from SMZL for a lower expression of CD20 and positivity for CD23.Mantle cell lymphoma Mantle cell lymphoma (MCL) is clinically different from SMZL due to the high frequency of peripheral lymphadenopathy, but some example of massive splenomegaly with bone marrow involvement without prominent lymphadenopathy can be observed. Neoplastic cells are small to medium sized with irregular nuclei, morphologically resembling centrocytes/cleaved follicular center cells, but with less irregular nuclear contours. The bone marrow infiltration can be interstitial, diffuse, or nodular; an intrasinusoidal component has never been observed. MCL is characteristically CD5+, CD43+, and cyclin D1+.
In contrast to the well-established chromosomal changes associated with other B-cell NHLs, few genetic alterations have been reported in association with SMZL and no consistent or unique abnormalities have been so far documented. IgVH mutations have been described and are consistent with their postfollicular marginal zone B-cell origin,51 whereas the occurrence of ongoing mutations could be acquired in the splenic environment.63 Recently, the study of matched splenic and blood neoplastic cells in 4 patients with SMZL showed identical VH sequences between cells from different tissues; 3 patients showed an unmutated germ line configuration, whereas the fourth one, who had developed a clonally related diffuse large B-cell lymphoma (DLBCL) of the chest wall, showed a significant somatic mutation of the subclone with intraclonal heterogeneity. This finding stresses the concept that an environmental factor can initiate in vivo somatic mutation, thus influencing tumor behavior and, possibly, disease progression.64 Rearrangement of bcl-6 was identified in some marginal zone lymphomas (MZLs),65 whereas another study did not confirm this finding.66 A molecular heterogeneity of SMZL has been therefore suggested, thus supporting the hypothesis that besides the proportion of cases derived from marginal zone cells, showing bcl-6 hypermutation, another significant proportion of cases could originate from an unmutated naive precursor possibly located in the mantle zone.67 The t(11;14), typical of MCL, was reported in some cases of SMZL leading to 2 possible explanations: (1) misdiagnosis because review of lymph node histology was not performed, and (2) a different bcl-1 breakpoint in SLVLs.68 Abnormalities of chromosome 14, at band q32.33 harboring the immunoglobulin heavy chain (IgH) gene, are found throughout among NHLs with different morphologic and clinical manifestations.69 The chromosomal abnormalities involving chromosome 14 more frequently encountered in patients with SLVLs were translocation t(6;14)70,71 and microdeletion of 13q14.72 The t(9;14)(p13;q32) translocation involves the IgH 14q32 in a head-to-head configuration to the PAX5 gene on chromosome 9p13. PAX5 normally codes for the transcription factor BSAP and is expressed from the earliest B-cell lymphopoiesis stages up to the mature B-cell stage with subsequent down-regulation during terminal plasma cell differentiation. The finding of t(9;14)(p13;q32) translocation in B-cell NHLs with plasmacytoid differentiation suggests that deregulation of PAX5 interferes with the cell cycle regulation of mature B cells and, by preventing them to enter the quiescent state, may contribute to the lymphomagenesis. This finding was reported in cases of SMZLs, whose origin is postulated to derive from transformed memory B cells of the marginal zone with potential of differentiation into plasma cells. The t(9;14)(p13;q32) translocation corresponds to a gain-of-function mutation of the human PAX5 gene with coding of a wild-type of BSAP protein.9 Structural abnormalities of 7q (7q32 deletions and 7q22 translocation),
commonly reported in myeloid malignancies, were found to occur in 3.6%
of patients with chronic lymphoproliferative disorders, mainly in
patients with SLVLs and HCL variant (26%).73 Moreover,
alterations of chromosome 7q, mainly allelic loss, are frequently
observed in splenic lymphomas74-77 with subsequent
dysregulation of cyclin-dependent kinase 6 (CDK6) gene,
possibly playing a role in the pathogenesis of SMZL and
SLVLs.78 The occurrence of 2 cytogenetic subtypes,
characterized, respectively, from gain of 3q and loss of 7q, was
suggested.79 Recently, by means of analysis of the
IgVH somatic mutations in SMZL, a significant group
(49%) of unmutated cases with frequent 7q The relationship between SMZL and MZLs arising at other sites, particularly those of mucosa-associated lymphoid tissue (MALT) type, has also been discussed. The t(11;18) (q21;q21), which represents the most frequent structural chromosomal alteration in extranodal low-grade MALT lymphomas, leads to a fusion between the apoptosis inhibitor-2 (API2) gene, on the chromosome 11 and the MALT lymphoma-associated translocation (MLT) gene on chromosome 18, thus prompting speculation about the critical role of abrogation of apoptosis in the development of these lymphomas.81,82 Despite the common pathogenesis postulated,83 no case of SMZL shows API2-MLT fusion, thus favoring the hypothesis of separate lymphoma entities.84-86 Similarly, the search in cases of SMZL for microsatellite instability, described in association with p53 mutation in patients with MZL of MALT type, gave negative results.87 This concept was further strengthened by the finding of different genetic alterations in MZLs arising at different sites, suggesting that fundamental differences exist between the subtypes of MZLs.88 Trisomy 3 represents the most frequent cytogenetic abnormalities reported in MZLs, occurring in a high proportion of extranodal, nodal, and splenic MZLs89,90 and SLVLs.91 In contrast with this finding, another study reported a high frequency of trisomy 3 in extranodal and nodal MZLs but not in splenic ones. This fact strengthens the idea that these different subtypes are genetically distinct.92 In some studies, the finding of cytogenetic alterations was put into
relationship with clinical course and prognosis. Translocations t(2;8)(p12;q24) and t(14;18)(q32;q21) were reported in a case of an
aggressive variant of SMZL.93 Complex chromosome defects including 6q Other studies, dealing with SMZL or SLVLs and cytogenetics, reported the expression of TCL1 oncogene, activated by recurrent reciprocal translocations at chromosome 14q32100 or the presence of a point mutation in the mtDNA tRNA methionine gene.101 In a recent paper, Bahler et al102 postulated the
existence of 2 different groups of SMZL, the first carrying unmutated
VH genes and showing IgD expression consistent with
a naïve B-cell origin and the other with mutated
VH genes and IgD
SMZL in animal models Some mouse lymphomas have strong histologic similarities with human SMZL.103 SMZLs have been found to occur spontaneously at a high frequency in particular strains of mice.104,105 In transgenic mice, in which a transcription factor derived from human lymphoblastic leukemia was placed in the DNA of their lymphocytes, a lymphoid expansion of splenic marginal zones was evident before the development of diffuse B-cell lymphoma.106 Clonal integration of murine leukemia virus is able to develop B-cell lymphoma in the splenic marginal zone.107 Homozygous p53-deficient mice develop SMZL, assessed with morphologic, immunohistochemical, flow cytometry, and immunoglobulin heavy-chain rearrangement techniques.108 However, the mechanism of lymphoma development in animal models remains undetermined.107 SMZL has been included in the Bethesda proposals for classification of lymphoid neoplasms in mice.109SMZL and infectious agents A high prevalence of a chronic liver disease, usually chronic hepatitis or cirrhosis, was described in Japan by Murakami et al110 in 1988 in a review of primary splenic lymphoma. Hepatitis C virus (HCV) has been observed in 36% of cases of primary splenic lymphoma.111 Satoh et al112 hypothesized a role of HCV infection in the development of primary splenic lymphoma after the description of a HCV+ patient whose spleen was grossly and histologically indistinguishable from SMZL. Other descriptions of SMZL in patients with HCV infection make this association more than casual.113-115 In nodal marginal lymphoma, HCV+ specimens harbor different VH somatic mutation compared to that of HCV ones, suggesting a role for a HCV antigen epitope in
the B-cell selection.116 The pathogenetic mechanism
underlying the development of SMZL during HCV infection remains
unexplained. HCV might provide the initial antigenic stimulus for
B-cell clonal expansion, as part of the multistep progression toward lymphomagenesis.
Abruzzo et al117 recently described data on a patient with SMZL, treated with fludarabine, who subsequently developed an Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorder. Raised EBV antibody levels without a concomitant increase in the detection of viral genomes in the peripheral blood has been demonstrated in tropical SLVL.118 A relationship between SLVL and malaria has been hypothesized.119 In West Africa, SLVL and hyperreactive malarial splenomegaly are demographically, clinically, and immunologically indistinguishable.120 Polymerase chain reaction (PCR) analysis of immunoglobulin genes can be useful in distinguishing the 2 conditions.121 Although the etiopathologic link is not yet fully understood, it is possible that an altered immune response to repeated malaria infections can stimulate or select a proliferating pool of naive B cells, altering their growth and apoptosis.122 Adhesion molecules The presence of its circulating counterpart, previously classified as SLVL, indicates that homing and circulation of neoplastic cells must be under the influence of adhesion molecule action.The migration and localization of lymphocytes from the blood into the
splenic white pulp is influenced by adhesive interactions, as evidenced
by the expression of adhesion molecules on sinus lining cells in the
marginal zone of the spleen.123 It is now clear that the
recruitment and retention of both T and B lymphocytes are based on
selective interactions involving several adhesion molecules like human
mucosal addressin cell adhesion molecule 1 (MAdCAM-1),124
whose expression is well documented in endothelial cells at mucosal
sites such as mesenteric lymph nodes, lamina propria of small and large
intestine and lactating mammary gland, and its exclusive integrin
receptor SLVL shows a low expression of L-selectin that represents a discordant feature if compared to the fact that all white pulp B cells, including marginal zone ones, are L-selectin positive.126 Moreover, in HCL, a pathologic condition closely related to SLVL, adhesion molecules have an important role in the interactions between hairy cells and endothelium/accessory cells in the red pulp of the spleen.131 The expression of a series of adhesion receptors (L-selectin, several integrins, ICAM-1, and CD44) investigated by means of flow cytometry in cases of both B-cell leukemic disorders and related lymphomas showed a reverse pattern of expression, namely, high expression of L-selectin and low expression of integrin molecules (leukocyte function associated antigen 1 [LFA-1], very late activation antigen 4 [VLA-4], ICAM-1) in CLL and low L-selectin positivity and high integrin expression in non-CLL disorders, including SMZL.132
To date there is no definitive standard treatment for SMZL. About two thirds of patients are asymptomatic at diagnosis and as many as one third will never require therapy. Both the selection and the timing of therapy are basically established on an empirical ground because of the indolent natural history of SMZL, the lack of prospective therapeutic trials, and the absence of response criteria and prognostic scores. There are 4 main types of initial treatment strategies: (1) no treatment, (2) splenic irradiation, (3) chemotherapy, and (4) splenectomy. In patients who do not undergo splenectomy the diagnosis is made with morphologic and immunophenotypical analysis of peripheral blood and bone marrow. No treatment Treatment abstention should be considered in patients with favorable prognostic factors. Patients with mild lymphocytosis and no cytopenia are in the eligible condition for the "wait and see" policy.6,13 In untreated patients the 5-year overall survival rate is 88%.16 Ten of 14 untreated patients of the series of Mulligan et al133 remained alive between 1 and 6 years from diagnosis. Patients with stable disease have been monitored for up to 15 years, without requiring any treatment.6Splenic irradiation Splenic irradiation has been used in a limited series of patients. Three of 7 patients in the Mulligan series benefited from splenic irradiation.133 Among the 7 patients treated by Troussard et al16 with 6 to 8 Gy with 1 or 2 fractions over 2 weeks, 3 had a relapse; none of the patients receiving only irradiation died. El Weshi et al134 reported that even low-dose radiotherapy (4 Gy) may be effective, producing a dramatic reduction in circulating villous lymphocytes, regression of splenomegaly, and improvement of cytopenias. Radiotherapy seems to be a reasonable and effective treatment option in SLVL when splenectomy is contraindicated and/or when pancytopenia is present and likely to give rise to excessive toxicity when chemotherapy is administered.Chemotherapy Many drugs with different schemes have been administered. There is no univocal convergence when and how to use chemotherapy. Chemotherapy is generally used as first-line treatment in patients with more advanced disease. The role of alkylating agents such as chlorambucil or cyclophosphamide is marginal. Few patients benefit when these are used as first-line therapy.6 However, in cases of disease progression, especially after splenectomy, alkylating agents may achieve good response, but seldom complete remission. Mean duration of response in patients treated with alkylating agents alone or in combination with other drugs is 6 months, whereas the 5-year overall survival rate is 64%.16 The use of purine analogues is more promising, but so far it has been tested in relatively few patients. Complete or partial hematologic remission has been achieved with 2-deoxycoformycin.135,136 Good responses with 2-chlorodeoxyadenosine have been also reported,137 whereas in other cases only partial responses with high frequency of relapses were obtained.138 Some complete remissions have been achieved with fludarabine as first- or second-line therapy.139-141Splenectomy There is a general consensus, as indicated by the 2 largest retrospective studies, in considering splenectomy the best first-line therapy.16,133 A huge symptomatic splenomegaly or a severe cytopenia or both are the main indications to perform splenectomy. Long and sustained improvement of cytopenia and relief of abdominal discomfort have been achieved with splenectomy alone. Moreover, in retrospective studies, splenectomized patients have a significantly better overall survival than those treated with chemotherapy.16 However, these data should be interpreted cautiously because this could be, at least partially, an expression of a selection bias, because patients with more aggressive disease are more likely to be treated with chemotherapy. Furthermore, it is intuitive that splenectomy alone cannot reduce extrasplenic lymphomatous infiltrations. Our group has reported a change in the bone marrow infiltration with increase in tumor burden after splenectomy.38 In particular, we demonstrated a modification from intrasinusoidal to nodular of the infiltrates in the bone marrow after splenectomy in most patients with SMZL. Conversely, in those patients who did not undergo splenectomy, bone marrow intrasinusoidal infiltration remained stable. Therefore, splenectomy seems to induce important changes in bone marrow infiltration, probably through the lack of microenvironmental homing factors on circulating B cells.Other modalities Additional treatment modalities such as single-agent rituximab are under investigation.142 Radiolabeled anti-CD20 monoclonal antibodies are currently in development for the treatment of low-grade B-cell NHLs.143 These include the iodine-labeled (tositumomab) and yttrium-labeled anti-CD20 (ibritumomab). Such approaches possess potential as future therapeutic agents but await investigations and clinical trials.The unexpected regression of SLVL in a HCV patient who was treated with
interferon-alfa for symptomatic type II cryoglobulinemia prompted
Hermine et al144 to evaluate the effect of interferon-alfa in 8 additional patients. Seven of 9 HCV+ patients with
SLVL had a complete hematologic remission after the loss of detectable
HCV-RNA, whereas none of HCV
The authors thank Dr M. Salvato for immunohistochemical stainings and Dr E. Barresi for the electron microscopy study.
Submitted July 23, 2002; accepted November 5, 2002.
Prepublished online as Blood First Edition Paper, November 21, 2002; DOI 10.1182/blood-2002-07-2216.
Supported by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Rome, Italy.
Reprints: Vito Franco, Istituto di Anatomia e
Istologia Patologica- Policlinico, Via del Vespro 129 90127 Palermo,
Italy; e-mail: vfranco{at}unipa.it.
1. Isaacson PG, Piris MA, Catovski D, et al. Splenic marginal zone lymphoma. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumors of Haematopoietic and Lymphoid tissues. WHO Classification of Tumors. Lyon, France: IARC Press; 2001:135-137.
2.
Pileri SA, Ascani S, Sabattini E, et al.
The pathologist's view point, part I: indolent lymphomas.
Haematologica.
2000;85:1291-1307 3. Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455-466[Medline] [Order article via Infotrieve]. 4. Melo JV, Robinson DS, Gregory C, Catovsky D. Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia. 1987;1:294-298[Medline] [Order article via Infotrieve].
5.
Isaacson PG, Matutes E, Burke M, Catovsky D.
The histopathology of splenic lymphoma with villous lymphocytes.
Blood.
1994;84:3828-3834 6. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148-154[Medline] [Order article via Infotrieve]. 7. Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology. 1996;29:571-575[CrossRef][Medline] [Order article via Infotrieve]. 8. Labouyrie E, Marit G, Vial J, et al. Intrasinusoidal bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol. 1997;10:1015-1020[Medline] [Order article via Infotrieve].
9.
Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M.
Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.
Blood.
1998;92:3865-3878 10. O'Reilly RA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med. 1998;169:88-97[Medline] [Order article via Infotrieve]. 11. Zucca E, Bertoni F, Roggero E, Cavalli F. Management of rare forms of lymphoma. Curr Opin Oncol. 1998;10:377-384[Medline] [Order article via Infotrieve]. 12. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795[Abstract].
13.
Berger F, Felman P, Thieblemont C, et al.
Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients.
Blood.
2000;95:1950-1956 14. Arber DA, Rappaport H, Weiss LM. Non-Hodgkin's lymphoproliferative disorders involving the spleen. Mod Pathol. 1997;10:18-32[Medline] [Order article via Infotrieve]. 15. Coad JE, Matutes E, Catovsky D. Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. Leuk Lymphoma. 1993;10:245-264[Medline] [Order article via Infotrieve]. 16. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731-736[CrossRef][Medline] [Order article via Infotrieve]. 17. Hammer RD, Glick AD, Greer JP, Collins RD, Cousar JB. Splenic marginal zone lymphoma. A distinct B-cell neoplasm. Am J Surg Pathol. 1996;20:613-626[CrossRef][Medline] [Order article via Infotrieve]. 18. de Figueiredo M, Lima M, Macedo G, Ribeiro P. Association of splenic lymphoma with villous lymphocytes and primary biliary cirrhosis in a man. Sangre (Barc). 1996;41:262-263[Medline] [Order article via Infotrieve]. 19. Takai K, Sanada M, Shibuya H. Primary splenic lymphoma complicated by malignant rheumatoid arthritis and bladder cancer. Rinsho Ketsueki. 1993;34:79-83[Medline] [Order article via Infotrieve]. 20. Murakami H, Irisawa H, Saitoh T, et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol. 1997;56:173-178[CrossRef][Medline] [Order article via Infotrieve]. 21. Van Huyen JP, Molina T, Delmer A, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol. 2000;24:1581-1592[Medline] [Order article via Infotrieve]. 22. Bonichon N, Lifermann F, Fossats A, Canteloup B, Dauzan Y. Autoimmune hemolytic anemia disclosing splenic lymphoma with villous lymphocyte [letter]. Presse Med. 1997;26:270[Medline] [Order article via Infotrieve]. 23. Gale R, Smith OP, Wood M, Mehta AB. Splenic lymphoma with villous lymphocytes complicated by autoimmune haemolytic anaemia [letter]. Lancet. 1992;340:1106[Medline] [Order article via Infotrieve].
24.
Bowen AL, Matutes E, Catovski D.
Splenic lymphoma with villous lymphocytes.
Haematologica.
1999;84(suppl 10):90-92 25. Zeidman A, Fradin Z, Barac Y, Bendayan D, Mittelman M, Orlin J. Splenic lymphoma presenting as warm autoimmune hemolytic anemia associated with pure red cell aplasia. Vox Sang. 2000;78:126-129[CrossRef][Medline] [Order article via Infotrieve]. 26. Farrell AM, Stern SC, El-Ghariani K, et al. Splenic lymphoma with villous lymphocytes presenting as leucocytoclastic vasculitis. Clin Exp Dermatol. 1999;24:19-22[CrossRef][Medline] [Order article via Infotrieve].
27.
Chacòn JI, Mollejo M, Muñoz E, et al.
Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients.
Blood.
2002;100:1648-1654 28. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41-47[Medline] [Order article via Infotrieve]. 29. Lloret E, Mollejo M, Mateo MS, et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum Pathol. 1999;30:1153-1160[CrossRef][Medline] [Order article via Infotrieve]. 30. Cualing H, Steele P, Zellner D. Blastic transformation of splenic marginal zone B-cell lymphoma. Arch Pathol Lab Med. 2000;124:748-752[Medline] [Order article via Infotrieve]. 31. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268-1276[CrossRef][Medline] [Order article via Infotrieve]. 32. Dierlamm J, Stefanova M, Wlodarska I, et al. Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: an interphase fluorescence in situ hybridization study. Cancer Genet Cytogenet. 2000;120:1-5[CrossRef][Medline] [Order article via Infotrieve]. 33. Pawade J, Wilkins BS, Wright DH. Low-grade B-cell lymphomas of the splenic marginal zone: a clinicopathological and immunohistochemical study of 14 cases. Histopathology. 1995;27:129-137[Medline] [Order article via Infotrieve]. 34. Mollejo M, Menarguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am J Surg Pathol. 1995;19:1146-1157[Medline] [Order article via Infotrieve]. 35. Wu CD, Jackson CL, Medeiros LJ. Splenic marginal zone cell lymphoma. An immunophenotypic and molecular study of five cases. Am J Clin Pathol. 1996;105:277-285[Medline] [Order article via Infotrieve]. 36. Mollejo M, Algara P, Mateo MS, et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 2002;40:22-30[CrossRef][Medline] [Order article via Infotrieve].
37.
Kent SA, Variakoijs D, Peterson LC.
Comparative study of marginal zone lymphoma involving bone marrow.
Am J Clin Pathol.
2002;117:698-708 38. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294-301[CrossRef][Medline] [Order article via Infotrieve]. 39. Mollejo M, Lloret E, Menarguez J, Piris MA, Isaacson PG. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am J Surg Pathol. 1997;21:772-780[CrossRef][Medline] [Order article via Infotrieve]. 40. Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59-68[CrossRef][Medline] [Order article via Infotrieve].
41.
Rosso R, Castello A, Colosini G, Astori C, Lazzarino M, Magrini U.
Splenic marginal zone cell lymphoma involving liver and bone marrow. Report of a case with protracted follow-up, showing progressive disappearance of the lymphoma after splenectomy.
Haematologica.
1996;81:44-46 42. Mollejo M, Algara P, Mateo MS, et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 2002;40:22-30[CrossRef][Medline] [Order article via Infotrieve]. 43. Orero MT, Miguel-Sosa A, Matutes E, et al. A soft tissue extranodal mass as an initial manifestation of splenic lymphoma with circulating villous lymphocytes [letter]. Br J Haematol. 1998;103:1213-1214[CrossRef][Medline] [Order article via Infotrieve]. 44. Yamazaki K, Shimizu S, Negami T, et al. Leukemic meningitis in a patient with splenic lymphoma with villous lymphocytes (SLVL). Meningitis as a possible initial manifestation of SLVL. Cancer. 1994;73:61-65[CrossRef]. 45. Gotlib V, Singareddy S, Gergis U, et al. Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2002;43:1337-1340[Medline] [Order article via Infotrieve]. 46. Rosso R, Neiman RS, Paulli M, et al. Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. Hum Pathol. 1995;26:39-46[CrossRef][Medline] [Order article via Infotrieve]. 47. Lai R, Weiss LM, Chang KL, Arber DA. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111:488-494[Medline] [Order article via Infotrieve].
48.
Dierlamm J, Pittaluga S, Wlodarska I, et al.
Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features.
Blood.
1996;87:299-307 49. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852[CrossRef][Medline] [Order article via Infotrieve]. 50. Salomon-Nguyen F, Valensi F, Troussard X, Flandrin G. The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Leuk Res. 1996;20:909-913[CrossRef][Medline] [Order article via Infotrieve]. 51. Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol. 1999;30:306-312[CrossRef][Medline] [Order article via Infotrieve]. 52. Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol. 1998;11:601-606[Medline] [Order article via Infotrieve]. 53. Swerdlow SH, Zukerberg LR, Yang WI, Harris NL, Williams ME. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol. 1996;20:627-640[CrossRef][Medline] [Order article via Infotrieve]. 54. Hoyer JD, Li CY, Yam LT, Hanson CA, Kurtin PJ. Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. Am J Clin Pathol. 1997;108:308-315[Medline] [Order article via Infotrieve]. 55. Chilosi M, Chiarle R, Lestani M, et al. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000;111:263-271[CrossRef][Medline] [Order article via Infotrieve].
56.
Quintanilla-Martinez L, Thieblemont C, Fend F, et al.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Am J Pathol.
1998;153:175-182 57. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95:627-632. 58. Falini B, Tiacci E, Hatzivassiliou G, et al. IRTA1: a new molecule associated with normal and neoplastic marginal zone cells [abstract]. J Clin Pathol 2002;55(suppl 1):A31-32. 59. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol. 1998;11:457-463[Medline] [Order article via Infotrieve]. 60. Miyawaki S, Machii T, Hirabayashi H, et al. Splenic lymphoma with villous lymphocytes with CD5+, CD11c+ B-cell phenotype. Intern Med. 1993;32:472-475[Medline] [Order article via Infotrieve]. 61. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452[CrossRef][Medline] [Order article via Infotrieve].
62.
Camacho FI, Garcia JF, Sanchez-Verde L, et al.
Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma.
Am J Pathol.
2001;158:1363-1369 63. Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol. 1998;29:585-593[CrossRef][Medline] [Order article via Infotrieve].
64.
Zhu D, Orchard J, Oscier DG, Wright DH, Stevenson FK.
VH gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo.
Blood.
2002;100:2659-2661 65. Dierlamm J, Pittaluga S, Stul M, et al. BCL6 gene rearrangements also occur in marginal zone B-cell lymphoma. Br J Haematol. 1997;98:719-725[CrossRef][Medline] [Order article via Infotrieve]. 66. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol. 1999;112:101-107[Medline] [Order article via Infotrieve]. 67. Mateo MS, Mollejo M, Villuendas R, et al. Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene. Leukemia. 2001;15:628-634[CrossRef][Medline] [Order article via Infotrieve]. 68. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 2001;15:1262-1267[CrossRef][Medline] [Order article via Infotrieve]. 69. Takashima T, Itoh M, Ueda Y, et al. Detection of 14q32.33 translocation and t(11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situ hybridization. Int J Cancer. 1997;72:31-38[CrossRef][Medline] [Order article via Infotrieve]. 70. Sole F, Espinet B, Salido M, et al. Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes [letter]. Br J Haematol. 2000;110:241-243[CrossRef][Medline] [Order article via Infotrieve].
71.
Sonoki T, Harder L, Horsman DE, et al.
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.
Blood.
2001;98:2837-2844
72.
Garcia-Marco JA, Nouel A, Navarro B, et al.
Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14.
Cancer Res.
1998;58:1736-1740 73. Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet Cytogenet. 1996;92:24-27[CrossRef][Medline] [Order article via Infotrieve]. 74. Wong KF, Chu YC, Hui PK. Splenic lymphoma with villous lymphocytes showing del(7) and inv(10). Cancer Genet Cytogenet. 1998;102:145-147[CrossRef][Medline] [Order article via Infotrieve]. 75. Fujita M, Uno H, Hino N, Nakagawa H, Nagaoka K, Sasaki N. Splenic lymphoma with villous lymphocytes expressing chromosomal abnormalities [abstract]. Rinsho Ketsueki. 1999;40:330-335[Medline] [Order article via Infotrieve]. 76. Sole F, Woessner S, Perez-Losada A, et al. Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Cancer Genet Cytogenet. 1997;93:160-166[CrossRef][Medline] [Order article via Infotrieve].
77.
Mateo M, Mollejo M, Villuendas R, et al.
7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.
Am J Pathol.
1999;154:1583-1589 78. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-6277[CrossRef][Medline] [Order article via Infotrieve]. 79. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71-77[Medline] [Order article via Infotrieve].
80.
Algara P, Mateo MS, Sanchez-Beato M, et al.
Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course.
Blood.
2002;99:1299-1304 81. Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol. 2000;18:1-13[CrossRef][Medline] [Order article via Infotrieve].
82.
Dierlamm J, Baens M, Stefanova-Ouzounova M, et al.
Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes.
Blood.
2000;96:2215-2218 83. de Wolf-Peeters C, Pittaluga S, Dierlamm J, Wlodarska I, Van Den Berghe H. Marginal zone B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone. Leuk Lymphoma. 1997;26:467-478[Medline] [Order article via Infotrieve].
84.
Rosenwald A, Ott G, Stilgenbauer S, et al.
Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas.
Am J Pathol.
1999;155:1817-1821
85.
Remstein ED, James CD, Kurtin PJ.
Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.
Am J Pathol.
2000;156:1183-1188
86.
Maes B, Baens M, Marynen P, de Wolf-Peeters C.
The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type.
Ann Oncol.
2000;11:521-526 87. Mateo MS, Mollejo M, Villuendas R, et al. Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. Mol Pathol. 1998;51:262-267[Abstract]. 88. Ott MM, Rosenwald A, Katzenberger T, et al. Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities. Genes Chromosomes Cancer. 2000;28:380-386[CrossRef][Medline] [Order article via Infotrieve].
89.
Wotherspoon AC, Finn TM, Isaacson PG.
Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.
Blood.
1995;85:2000-2004 90. Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybridization. Br J Haematol. 1996;93:242-249[CrossRef][Medline] [Order article via Infotrieve]. 91. Gruszka-Westwood AM, Matutes E, Coignet LJ, Wotherspoon A, Catovsky D. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol. 1999;104:600-604[CrossRef][Medline] [Order article via Infotrieve]. 92. Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol. 1996;9:995-1000[Medline] [Order article via Infotrieve]. 93. Batanian JR, Dunphy CH, Richart JM, Petruska PJ, Perkins SL. Simultaneous presence of t(2;8)(p12;q24) and t(14;18)(q32;q21) in a B-cell lymphoproliferative disorder with features suggestive of an aggressive variant of splenic marginal-zone lymphoma. Cancer Genet Cytogenet. 2000;120:136-140[CrossRef][Medline] [Order article via Infotrieve].
94.
Cuneo A, Bigoni R, Roberti MG, et al.
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases.
Haematologica.
2001;86:64-70
95.
Hernandez JM, Garcia JL, Gutierrez NC, et al.
Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.
Am J Pathol.
2001;158:1843-1850 96. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG. Genetic instability leads to loss of both p53 alleles in human glioblastoma. Oncogene. 1998;16:321-326[CrossRef][Medline] [Order article via Infotrieve].
97.
Bea S, Lopez-Guillermo A, Ribas M, et al.
Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome).
Am J Pathol.
2002;161:957-968
98.
Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D.
p53 abnormalities in splenic lymphoma with villous lymphocytes.
Blood.
2001;97:3552-3558 99. Baldini L, Guffanti A, Cro L, et al. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol. 1997;99:375-378[CrossRef][Medline] [Order article via Infotrieve]. 100. Yuille MR, Condie A, Stone EM, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer. 2001;30:336-341[CrossRef][Medline] [Order article via Infotrieve]. 101. Lombes A, Bories D, Girodon E, et al. The first pathogenic mitochondrial methionine tRNA point mutation is discovered in splenic lymphoma. Hum Mutat. 1998;11:S175-183[CrossRef].
102.
Bahler DW, Pindzola JA, Swerdlow SH.
Splenic marginal zone lymphomas appear to originate from different B cell types.
Am J Pathol.
2002;161:81-88 103. Hori M, Xiang S, Qi CF, et al. Non-Hodgkin lymphomas of mice. Blood Cells Mol Dis. 2001;27:217-222[CrossRef][Medline] [Order article via Infotrieve].
104.
Fredrickson TN, Lennert K, Chattopadhyay SK, Morse HC 3rd, Hartley JW.
Splenic marginal zone lymphomas of mice.
Am J Pathol.
1999;154:805-812 105. Tang JC, Ho FC, Chan AC, Chow EY, Srivastava G. Progression of spontaneous lymphomas in SJL mice: monitoring in vivo clonal evolution with molecular markers in sequential splenic samples. Lab Invest. 1998;78:1459-1466[Medline] [Order article via Infotrieve].
106.
Hough MR, Reis MD, Singaraja R, et al.
A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice.
Proc Natl Acad Sci U S A.
1998;95:13853-13858 107. Hartley JW, Chattopadhyay SK, Lander MR, et al. Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses. Lab Invest. 2000;80:159-169[Medline] [Order article via Infotrieve]. 108. Ward JM, Tadesse-Heath L, Perkins SN, Chattopadhyay SK, Hursting SD, Morse HC 3rd. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest. 1999;79:3-14[Medline] [Order article via Infotrieve].
109.
Morse HC III, Anver MR, Fredrickson N, et al.
Bethesda proposals for classification of lymphoid neoplasms in mice.
Blood.
2002;100:246-258 110. Murakami Y, Hotei H, Tsumura H, et al. A case of primary splenic malignant lymphoma and review of 98 cases reported in Japan [abstract]. J Jpn Soc Clin Surg. 1988;49:716-719. 111. Kumagawa M, Suzumiya J, Ohshima K, Kanda M, Tamura K, Kikuchi M. Splenic lymphoproliferative disorders in human T lymphotropic virus type-I endemic area of Japan: clinicopathological, immunohistochemical and genetic analysis of 27 cases. Leuk Lymphoma. 2001;41:593-605[Medline] [Order article via Infotrieve]. 112. Satoh T, Yamada T, Nakano S, et al. The relationship between primary splenic malignant lymphoma and chronic liver disease associated with hepatitis C virus infection. Cancer. 1997;80:1981-1988[CrossRef][Medline] [Order article via Infotrieve]. 113. Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int. 1999;14:288-293[Medline] [Order article via Infotrieve]. 114. Luppi M, Ferrari MG, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia. 1996;10:351-355[Medline] [Order article via Infotrieve].
115.
Silvestri F, Barillari G, Fanin R, et al.
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas.
Haematologica.
1997;82:314-317
116.
Marasca R, Vaccari P, Luppi M, et al.
Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma.
Am J Pathol.
2001;159:253-261 117. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002;26:630-636[CrossRef][Medline] [Order article via Infotrieve]. 118. Bates I, Bedu-Addo G, Jarrett RF, et al. B-lymphotropic viruses in a novel tropical splenic lymphoma. Br J Haematol. 2001;112:161-166[CrossRef][Medline] [Order article via Infotrieve].
119.
Bates I, Bedu-Addo G, Rutherford TR, Bevan DH.
Circulating villous lymphocytes 120. Wallace S, Bedu-Addo G, Rutherford TR, Bates I. Serological similarities between hyperreactive malarial splenomegaly and splenic lymphoma in west Africa. Trans R Soc Trop Med Hyg. 1998;92:463-467[CrossRef][Medline] [Order article via Infotrieve]. 121. Jimmy EO, Bedu-Addo G, Bates I, Bevan D, Rutherford TR. Immunoglobulin gene polymerase chain reaction to distinguish hyperreactive malarial splenomegaly from "African" chronic lymphocytic leukaemia and splenic lymphoma. Trans R Soc Trop Med Hyg. 1996;90:37-39[CrossRef][Medline] [Order article via Infotrieve]. 122. Zhu D, Thompsett AR, Bedu-Addo G, Stevenson FK, Bates I. VH gene sequences from a novel tropical splenic lymphoma reveal a naive B cell as the cell of origin. Br J Haematol. 1999;107:114-120[CrossRef][Medline] [Order article via Infotrieve].
123.
Steiniger B, Barth P, Hellinger A.
The perifollicular and marginal zones of the human splenic white pulp.
Am J Pathol
2001;159:501-512 124. Kraal G, Schornagel K, Streeter PR, et al. Expression of the mucosal vascular addressin, MAdCAM-1, on sinus lining cells of the spleen. Am J Pathol. 1995;147:763-771[Abstract]. 125. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110[Abstract].
126.
Munro JM, Briscoe DM, Tedder TF.
Differential regulation of leukocyte L-selectin (CD62L) expression in normal lymphoid and inflamed extralymphoid tissues.
J Clin Pathol.
1996;49:721-727 127. Mohle R, Murea S, Kirsch M, Haas R. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol. 1995;23:1535-1542[Medline] [Order article via Infotrieve]. 128. Papayannopoulou T, Craddock C. Homing and trafficking of hemopoietic progenitor cells. Acta Haematol. 1997;97:97-104[Medline] [Order article via Infotrieve]. 129. Voermans C, van Hennick PB, van der Schoot CE. Homing of human stem and progenitor cells: new insights, new challenges? J Hematother Stem Cell Res. 2001;10:725-738[CrossRef][Medline] [Order article via Infotrieve].
130.
Frenette PS, Subbarao S, Mazo IB, et al.
Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow.
Proc Natl Acad Sci U S A.
1998;95:14423-14428
131.
Vincent AM, Burthem J, Brew R, Cawley JC.
Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder.
Blood.
1996;88:3945-3952 132. Csanaky G, Matutes E, Vass JA, et al. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leucemia. 1997;11:408-415 133. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206-209[Medline] [Order article via Infotrieve]. 134. El Weshi A, Ribrag V, Girinski T, El Hajj M, Dhermain F, Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103:1212-1213[CrossRef][Medline] [Order article via Infotrieve]. 135. Matutes E. Catovski D. Clinical and laboratory features of splenic lymphoma with villous lymphocytes. In Armitage JO, Newland A, Keatty A, et al, eds. Cambridge Medical Reviews Haematology Oncology. Vol.4 Cambridge United Kingdom: Cambridge University Press; 1993:149-150.
136.
Iannitto E, Cirrincione S, Pagliaro M, et al.
Pentostatin in the treatment of splenic lymphoma with villous lymphocytes. A phase II study. Preliminary results [abstract].
Blood.
2001;98:558 137. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA) [letter]. Br J Haematol. 1998;100:609[CrossRef][Medline] [Order article via Infotrieve]. 138. Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40:113-117[Medline] [Order article via Infotrieve]. 139. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997;99:158-161[CrossRef][Medline] [Order article via Infotrieve]. 140. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000;14:573-575[CrossRef][Medline] [Order article via Infotrieve]. 141. Tchiknavorian X, Otto J, Pivot X, Arnaud MC, Schneider M, Thyss A. Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin. Hematol Cell Ther. 1999;41:233-234[CrossRef][Medline] [Order article via Infotrieve]. 142. Thomas DA, O'Brien S, Cortes J, et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal lymphoma (MZL) with single agent rituximab [abstract]. Blood. 2001;98:563. 143. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201[Medline] [Order article via Infotrieve].
144.
Hermine O, Lefrere F, Bronowicki J-P, et al.
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.
N Engl J Med.
2002;347:89-94   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
and adverse clinical
course was reported,
4
a link between hyperreactive malarial splenomegaly and splenic lymphoma.
Trans R Soc Trop Med Hyg.
1997;91:171-174
